2415307
Cooperative Agreement
Overview
Grant Description
SBIR Phase II: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project involves developing a personalized home-based treatment for autistic children.
Autism spectrum disorder is a common neurodevelopmental disorder requiring lifelong management.
The prevalence rate is globally rising, with nearly 3% of U.S. children afflicted.
A lack of clinically validated solutions places a heavy emotional and financial burden on families, with annual costs of care projected to reach $461 billion by 2025.
Autism currently has no approved medications or medical device treatments for core symptoms, and the only current treatment is intensive behavioral therapy.
This project aims to develop an effective personalized treatment for improving communication, learning, and social skills, thereby increasing individual independence, creating new employment opportunities, and reducing government spending on special education and support services.
Additionally, it aims to enrich knowledge through personalization, monitoring, and data aggregation of neurological measures for further elucidating the mechanisms of autism and enhancing the efficacy of other therapies.
This Small Business Innovation Research (SBIR) Phase II project aims to develop a non-invasive therapeutic brain stimulation medical device to improve the communication, responsiveness, and social integration of autistic children.
The project's objectives are to finalize the current prototype into a manufacturing-ready product and implement a platform for personalizing transcranial photobiomodulation (TPBM) treatment based on individual sensor-derived patient characteristics.
The proposed development consists of two main technological components: the first is a wearable device worn on a child’s head that delivers transcranial photobiomodulation (TPBM) therapy to reduce autism symptoms based on integrated electroencephalogram (EEG) measures.
The second is a software and data platform providing analyzed reports to evaluate intervention efficacy and personalize treatment through machine learning.
The anticipated technical results include completion of the final version of the device suitable for clinical adoption and future approval.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project involves developing a personalized home-based treatment for autistic children.
Autism spectrum disorder is a common neurodevelopmental disorder requiring lifelong management.
The prevalence rate is globally rising, with nearly 3% of U.S. children afflicted.
A lack of clinically validated solutions places a heavy emotional and financial burden on families, with annual costs of care projected to reach $461 billion by 2025.
Autism currently has no approved medications or medical device treatments for core symptoms, and the only current treatment is intensive behavioral therapy.
This project aims to develop an effective personalized treatment for improving communication, learning, and social skills, thereby increasing individual independence, creating new employment opportunities, and reducing government spending on special education and support services.
Additionally, it aims to enrich knowledge through personalization, monitoring, and data aggregation of neurological measures for further elucidating the mechanisms of autism and enhancing the efficacy of other therapies.
This Small Business Innovation Research (SBIR) Phase II project aims to develop a non-invasive therapeutic brain stimulation medical device to improve the communication, responsiveness, and social integration of autistic children.
The project's objectives are to finalize the current prototype into a manufacturing-ready product and implement a platform for personalizing transcranial photobiomodulation (TPBM) treatment based on individual sensor-derived patient characteristics.
The proposed development consists of two main technological components: the first is a wearable device worn on a child’s head that delivers transcranial photobiomodulation (TPBM) therapy to reduce autism symptoms based on integrated electroencephalogram (EEG) measures.
The second is a software and data platform providing analyzed reports to evaluate intervention efficacy and personalize treatment through machine learning.
The anticipated technical results include completion of the final version of the device suitable for clinical adoption and future approval.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23516
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New York,
New York
10005-2201
United States
Geographic Scope
Single Zip Code
Jelikalite was awarded
Cooperative Agreement 2415307
worth $959,066
from National Science Foundation in September 2024 with work to be completed primarily in New York New York United States.
The grant
has a duration of 2 years and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Cooperative Agreement was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase II Programs (SBIR/STTR Phase II).
SBIR Details
Research Type
SBIR Phase II
Title
SBIR Phase II: EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project involves developing a personalized home-based treatment for autistic children. Autism Spectrum Disorder is a common neurodevelopmental disorder requiring lifelong management. The prevalence rate is globally rising, with nearly 3% of U.S. children afflicted. A lack of clinically validated solutions places a heavy emotional and financial burden on families with annual costs of care projected to reach $461 billion by 2025. Autism currently has no approved medications or medical device treatments for core symptoms, and the only current treatment is intensive behavioral therapy. This project aims to develop an effective personalized treatment for improving communication, learning, and social skills, thereby increasing individual independence, create new employment opportunities, and reduce government spending on special education and support services. Additionally, it aims to enrich knowledge through personalization, monitoring, and data aggregation of neurological measures for further elucidating the mechanisms of autism and enhancing the efficacy of other therapies.
This Small Business Innovation Research (SBIR) Phase II project aims to develop a non-invasive therapeutic brain stimulation medical device to improve the communication, responsiveness, and social integration of autistic children. The project's objectives are to finalize the current prototype into a manufacturing-ready product, and implement a platform for personalizing transcranial photobiomodulation (tPBM) treatment based on individual sensor derived patient characteristics. The proposed development consists of two main technological components - The first is a wearable device worn on a child’s head that delivers transcranial Photobiomoldulation (tPBM) therapy to reduce autism symptoms based on integrated electroencephalogram (EEG) measures - The second is a software and data platform providing analyzed reports to evaluate intervention efficacy and personalize treatment through machine learning. The anticipated technical results include completion of the final version of the device suitable for clinical adoption and future approval.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 23-516
Status
(Ongoing)
Last Modified 9/17/24
Period of Performance
9/1/24
Start Date
8/31/26
End Date
Funding Split
$959.1K
Federal Obligation
$0.0
Non-Federal Obligation
$959.1K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2415307
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
EM6KAHVY78N3
Awardee CAGE
8CJX4
Performance District
NY-10
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Modified: 9/17/24